<DOC>
	<DOCNO>NCT01905683</DOCNO>
	<brief_summary>The purpose study determine whether injection Botulinum toxin type A muscle leg ( ) leg ( ) one arm safe treating children/adolescents ( age 2-17 year ) long-term increased muscle tension/uncontrollable muscle stiffness ( spasticity ) due cerebral palsy .</brief_summary>
	<brief_title>Long-term Open-label Study Botulinumtoxin Type A Treat Spasticity Leg ( ) Leg ( ) Arm Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Main clinical inclusion criterion completers study MRZ60201_3070_1 : Subject low limb [ LL ] spasticity complete leadin study MRZ60201_3070_1 three dose group duration injection cycle 12 16 week . Ashworth scale [ AS ] score ≥2 plantar flexor ( least unilaterally ) . For subject AS score 1 , investigator decide clinical need reinjection . Clinical need spasticity treatment NT 201 accord clinical judgment investigator : Unilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) pes equinus need additional 8 U/kg BW NT 201 ( maximum 200 U ) treatment clinical pattern flex knee adduct thigh ( ipsilateral ) bilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) pes equinus side . No treatment clinical pattern allow . Main clinical inclusion criterion subject participate MRZ60201_3070_1 : Female male subject 2 17 year age ( inclusive ) . Uni bilateral CP clinical need BoNT injection treat limb spasticity . AS score ≥ 2 plantar flexor ( least unilaterally ) . Clinical need accord clinical judgment investigator one four treatment combination : 1 . For LL ( ) treatment ( Gross Motor Function Classification System [ GMFCS ] level IV ) : Unilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) pes equinus , 8 U/kg BW NT 201 ( maximum 200 U ) flex knee adduct thigh bilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) pes equinus ( AS score ≥ 2 side ) . 2 . For combined unilateral UL unilateral LL , ( GMFCS level IIII ) : Unilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) pes equinus , 8 U/kg BW NT 201 ( maximum 200 U ) flex knee adduct thigh plus Unilateral treatment UL spasticity 4 U/kg BW NT 201 ( maximum 100 U ) flex elbow , flexed wrist , clench fist , thumb palm and/or pronate forearm . 3 . For combined unilateral UL unilateral LL ( GMFCS level IVV ) : Unilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) pes equinus , 4 U/kg BW NT201 ( maximum 100 U ) flex knee adduct thigh plus unilateral treatment UL spasticity 4 U/kg BW NT 201 ( maximum 100 U ) flex elbow , flexed wrist , clench fist , thumb palm and/or pronate forearm . 4 . For combined unilateral UL bilateral LL ( GMFCS level IIII ) : Bilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) pes equinus ( AS score ≥ 2 side ) plus unilateral treatment UL spasticity 4 U/kg BW NT 201 ( maximum 100 U ) flex elbow , flexed wrist , clench fist , thumb palm and/or pronate forearm . Exclusion Criteria subject complete MRZ60201_3070_1 : Infection and/or inflammation area plan injection point . Pregnancy female history menarche . Clinically relevant pathological finding indicate active disease vital organ . Exclusion Criteria subject participate MRZ60201_3070_1 : Fixed contracture define severe restriction range joint movement passive stretch target clinical pattern ( ) predominant form muscle hypertonia spasticity ( e.g. , dystonia ) target limb ( ) . Surgery pes equinus side ( ) intend treat BoNT injection within 12 month prior Screening Visit ( V1 ) , within screen period plan time participation study . Hip flexion require BoNT injection . Limitation hip abduction le 40° prediagnosed migrational percentage great 30 . Vaccination within 2 week prior Screening Visit ( V1 ) and/or within screen period . Nonresolved fracture treat limb . Ventilator dependency . Severe neurological diagnosis comorbidity outside spectrum cerebral palsy . Pure dyskinetic CP mixed CP predominantly dyskinetic movement . Treatment BoNT ( study drug study ) body region within 14 week prior Screening Visit ( V1 ) , within screen period and/or intend administer study period . Treatment phenol alcohol muscle within 6 month prior Screening Visit ( V1 ) , within screen period , and/or intend administer study period . Treatment drug act peripheral muscle relaxant intrathecal baclofen , oral anticoagulant administer within 2 week prior Screening Visit ( V1 ) , within screen period , and/or intend administer study period .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>